DDInter1789 DDInter1376
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Thalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Thalidomide {u} (Compound) binds {v} (Gene) FGFR2
Thalidomide {u} (Compound) upregulates {v} (Gene) TGFBR2
Thalidomide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologically Active Molecule Activity
Thalidomide {u} (Compound) downregulates {v} (Gene) ARNT2
Thalidomide {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Thalidomide (Compound) resembles Lenalidomide (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease)
Thalidomide (Compound) binds FGFR2 (Gene)
Thalidomide (Compound) upregulates TGFBR2 (Gene)
Thalidomide (Compound) is included by Decreased Immunologically Active Molecule Activity (Pharmacologic Class)
Thalidomide (Compound) downregulates ARNT2 (Gene)
Thalidomide (Compound) causes Myocardial ischaemia (Side Effect)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Astemizole
Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine